VC-backed Biosergen raises €5m via unit offering ahead of IPO
VC-backed biotech company Biosergen has raised SEK 50m (€5m) via a unit offering and is planning to list later this month.
The company, which is backed by Östersjöstielsen (The Baltic Sea Foundation), Rosetta Capital, Sintef Venture and Karolinska Development, will use the the proceeds from the offering to launch clinical trials of its antifungal drug candidate BSG005 with the plan of filing for market approval in the US and Europe by the end of 2025.
The company expects to start trading on Nasdaq First Growth Market on 24 June.
Östersjöstielsen, Rosetta and Sintef together hold a 91.2% stake in Biosergen, while Karolinska Development owns 3.2%.
Company
Founded in 2004 and based in Solna, Biosergen is a biotech company developing new antifungal drugs for the treatment of severe invasive fungal infections.
Advisers
Company – Lindahl (legal).
More on Exits
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Ares Management handed keys to two-thirds of UK sponsor’s portfolio
Lender provided GBP 500m for three of the GP's deals between 2016 and 2019, Debtwire reported
Actera Group explores strategic options for Celebi Ground Handling
Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal
Main Capital’s Assessio to be sold to Pollen Street
Recruitment software company tripled in revenue under Main Capital’s ownership
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater